Prana and Takeda to conduct preclinical research to treat PD gastrointestinal symptoms

Prana Biotechnology Ltd. (ASX:PBT; NASDAQ:PRAN) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) partnered to study the ability of Prana's PBT434 to slow or prevent gastrointestinal dysfunction in mouse models, including an alpha-synuclein transgenic mouse. Prana said neurodegeneration of the gastrointestinal system is "one of the important non-motor features of Parkinson’s disease."

Data published in Acta Neuropathologica Communications suggests PBT434 may restore motor function in animal models of PD...